Active pharmaceutical ingredients need to

International sustainable development urgently need new mode of "two high" left to change - that is, realize the "high technology content, high added value and quality level surplus (quality standards)" business goals. Use of new and high technology, further optimize the traditional API manufacturing process, improve bulk API technology content.

In 2011 world conference on pharmaceutical apis (Shanghai) exhibition CPHI China has been in an atmosphere of "a cold one hot" in the end. The cold is the API price is still in the low and even a record low, domestic demand for active pharmaceutical ingredients enterprise attendance has decreased; Heat is relatively flat, although the market demand but the enthusiasm of foreign exhibitors are generally high.

API prices are low, all is the result of excess capacity and the imbalance of supply and demand under the fierce competition, and the enthusiasm of the foreign exhibitors, is about to or already fell into trough new buying opportunities. "A cold one hot", once again remind local drug firms, API management concept of internationalization development need to develop new ideas, rational to seek a new way out.

Big and not strong, the old model restricts the internationalization level

Relying on strong technical imitation ability and good resources cost advantage, China API market with the rapid development of the world's attention. China has already can produce more than 1500 kinds of chemical pharmaceuticals, among them, more than 60 API has strong competitiveness in the international market. Vitamin C, vitamin E, penicillin and cephalosporin, antipyretic analgesic, such as bulk active pharmaceutical ingredients, a significant absolute advantage in the world.

Bulk API production, however, the inherent characteristics of "two high left", namely "energy-intensive, highly polluting, and excess capacity" of the status quo, always restricts the sustainable development of domestic API. Apis and intermediates exports is very large, profit level is low, after a spate of trade friction; API short horse pharmaceutical enterprise profit fast, sustained profitability is not enough, the production and business operation fluctuation is volatile.

In the first quarter this year, the API exported $5.363 billion in China, up 31.31%; API's overall exports growth is driven by export quantity, growth reached 39.53%, export prices have declined by 5.89%.

Internationalization of China's active pharmaceutical ingredients, improve, should not only in quantity, but should reflect more on the quality. "Go global" is not equal to "towards a top-grade", only if the API production technology and quality standard is low, the production process of environmental protection and safety guarantee system is only a low level or transient, so China API international brand marketing is still a long way to go.

International sustainable development urgently need new mode of "two high" left to change - that is, realize the "high technology content, high added value and quality level surplus (quality standards)" business goals. Use of new and high technology, further optimize the traditional API manufacturing process, improve bulk API technology content.

New mode of "two high" left will promote the pharmaceutical enterprises have more independent intellectual property rights and better quality assurance system, and win more favorable competition initiative, out of the "only wandered the value of the industrial chain of low-end and subjugation" business depression.

The establishment of the new model, need active pharmaceutical ingredients of pharmaceutical companies actively promote and self-discipline management, also needs the scientific guidance of all kinds of industrial policy and regulation. On the one hand, the need for government support API pharmaceutical enterprise upgrading traditional product technology and quality standards; On the other hand, also need to increase the "two high" left API approval access and regulation of quality, safety and environmental protection system. For some large key API production run level for regular review of national regulatory authorities, to promote the industrial structure adjustment guidance catalogue "left ban" effectively play a role. At the same time, the industry association should also cooperate with regular market operation early warning information release, to avoid disorderly competition and repeated construction, lead drug firms scientific investment, rational competition.

In the second quarter, pharmaceutical exports could have declined year-on-year growth, due to early medicine excessively rapid growth of exports, there will be a part of the API product "periodic surplus", to export prices and incremental will form a certain inhibition. Combined with the present domestic medical market under the new medical reform policies, such as price, demand for temporary not flourishing, industry reflects the medical market to sell into the new stagnation, operating difficulties and profit more and more heavy pressure.